CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 y Primary Prevention of Heart Failure in Women Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus

Review ArticleVolume 74, Issue 5, August 2019

JOURNAL:J Am Coll Cardiol. Article Link

Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5)

FWA Verheugt, JM ten Berg, RF Storey et al.

ABSTRACT

For secondary prevention of coronary artery disease (CAD), oral antiplatelet therapy is essential. In case of coronary intervention, temporary dual antiplatelet therapy is mandatory as well. Recently, low-dose oral anticoagulation has entered the CAD arena. Atrial fibrillation (AF) is often seen in CAD and vice versa. In most patients stroke prevention in AF consists of oral anticoagulation. In many cases of CAD in patients with AF, anticoagulation has to be combined with antiplatelet agents (so called, dual pathway antithrombotic therapy). Excess bleeding in these conditions is a rapidly rising problem. This review addresses the antithrombotic options in CAD alone, in AF alone, and in their combination, when either an invasive or a noninvasive approach has been chosen.